Abstract
Background. Despite existing clinical guidelines, representative data on breast cancer outcomes in patients aged 25 years and younger remain limited. Aim. To analyze long-term survival in this age group. Materials and methods. We conducted a retrospective, multicenter study that included patients treated between 2008 and 2020. From 552 tracked cases, 2 groups matched by disease stage and tumor molecular subtypes were formed using 1:2 pseudo-randomization: the study group (n = 63, age ≤ 25 years) and the control group (n = 126, age 25 years). The distribution of clinical stages was identical in both groups: in the study group, stage IA was observed in 11 patients (17.5 %), IIA in 18 (28.6 %), IIB in 13 (20.6 %), IIIA in 6 (9.5 %), IIIB in 7 (11.1 %), and IIIC in 8 (12.7 %); in the control group the corresponding numbers were 22, 36, 26, 12, 14, and 16 cases, respectively (the same proportions). Overall survival and recurrence-free survival (RFS) were assessed. Results. The analysis revealed a statistically significant decrease in RFS in the group of young patients. The median RFS was 73.9 months compared to 82.8 months in the control group, which is consistent with the survival analysis results (p = 0.027). The 5-year RFS was significantly lower – 55.7 % versus 77.1 %, and the 10-year RFS was 36.3 % versus 49.8 % (p = 0.027). Regarding overall survival, although the median and 5-year survival rates in the ≤ 25 years group were also lower (149.7 months and 79 % versus 157.3 months and 89 %, respectively), the difference did not reach statistical significance (p = 0.229). Conclusion. Patients with breast cancer aged ≤ 25 years have significantly lower recurrence-free survival, confirming the concept of more aggressive disease course in young age, likely associated with adverse biological features of the tumors. These findings underscore the need to identify modifiable prognostic factors and develop more effective treatment strategies for this patient category.

This publication has 11 references indexed in Scilit: